Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment

BACKGROUND: Vaccine immunotherapy may improve survival in Glioblastoma (GBM). A multicenter phase II trial was designed to determine: (1) the success rate of manufacturing the Aivita GBM vaccine (AV-GBM-1), (2) Adverse Events (AE) associated with AV-GBM-1 administration, and (3) survival. METHODS: F...

Descripción completa

Detalles Bibliográficos
Autores principales: Bota, Daniela A., Taylor, Thomas H., Piccioni, David E., Duma, Christopher M., LaRocca, Renato V., Kesari, Santosh, Carrillo, Jose A., Abedi, Mehrdad, Aiken, Robert D., Hsu, Frank P. K., Kong, Xiao-Tang, Hsieh, Candace, Bota, Peter G., Nistor, Gabriel I., Keirstead, Hans S., Dillman, Robert O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749349/
https://www.ncbi.nlm.nih.gov/pubmed/36517865
http://dx.doi.org/10.1186/s13046-022-02552-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749349/
https://www.ncbi.nlm.nih.gov/pubmed/36517865
http://dx.doi.org/10.1186/s13046-022-02552-6

Ejemplares similares